Prihlásiť sa Zaregistrujte sa zadarmo

Príjmy spoločnosti Financière de Tubize SA

Aká je hodnota metriky Príjmy spoločnosti Financière de Tubize SA?

Hodnota metriky Príjmy spoločnosti Financière de Tubize SA je €319.735M

Aká je definícia metriky Príjmy?

Výsledok príjmov pre kmeňových akcionárov (Income) sa rovná celkovému príjmu mínus vyplatené prioritné dividendy.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Príjmy spoločností v sektore Health Care sektor na EURONEXT v porovnaní so spoločnosťou Financière de Tubize SA

Čomu sa venuje spoločnosť Financière de Tubize SA?

Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.

Firmy s metrikou príjmy podobnou spoločnosti Financière de Tubize SA